[go: up one dir, main page]

PE20050414A1 - Formulacion farmaceutica oral que comprende un antagonista de la bomba de protones y un excipiente basico - Google Patents

Formulacion farmaceutica oral que comprende un antagonista de la bomba de protones y un excipiente basico

Info

Publication number
PE20050414A1
PE20050414A1 PE2004000357A PE2004000357A PE20050414A1 PE 20050414 A1 PE20050414 A1 PE 20050414A1 PE 2004000357 A PE2004000357 A PE 2004000357A PE 2004000357 A PE2004000357 A PE 2004000357A PE 20050414 A1 PE20050414 A1 PE 20050414A1
Authority
PE
Peru
Prior art keywords
flavors
capsules
granules
dimethyl
pharmaceutical formulation
Prior art date
Application number
PE2004000357A
Other languages
English (en)
Inventor
Rango Dietrich
Bernd-Michael Haas
Simone Hiltl
Hartmut Ney
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33160619&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050414(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10317023A external-priority patent/DE10317023A1/de
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of PE20050414A1 publication Critical patent/PE20050414A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA FORMA DE DOSIFICACION POR VIA ORAL, ESTABLES, PARA AGENTES ANTAGONISTAS DE BOMBAS DE PROTONES (APAs), SIENDO SELECCIONADOS LOS COMPUESTOS: AU-461, 7R,8R,9R)-2,3-DIMETIL-8-HIDROXI-7-(2-METOXIETOXI)-9-FENIL-7,8,9,10-TETRAHIDROIMIDAZO[1,2-h][1,7]NAFTIRIDINA (INN SORAPRAZANO), DBM-819, KR-60436, T-330, YH-1885, YJA-20379-8 Y 2,3-DIMETIL-8-(2-ETIL-6-METILBENCILAMINO)IMIDAZOL[1,2-a]PIRIDINA-6-CARBOXAMIDA, EN EL CUAL ESTE AGENTE ES ESTABILIZADO MEDIANTE UN EXCIPIENTE DE CARACTER BASICO TALES COMO CARBONATO DE SODIO, CARBONATO DE CALCIO, CARBONATO DE MAGNESIO, OXIDO DE MAGNESIO, HIDROXIDO DE MAGNESIO, ENTRE OTROS, LOS QUE ESTAN PRESENTES EN FORMA FINAMENTE DIVIDIDA Y MEZCLADOS A FONDO CON EL AGENTE, OBTENIENDOSE UNA FORMA DE DOSIFICACION QUE SE DESINTEGRA CON RAPIDEZ CON UNA LIBERACION INMEDIATA DEL INGREDIENTE ACTIVO, ADEMAS PRESENTAN POR LO MENOS UN MATERIAL DE RELLENO Y UN AGENTE DESINTEGRANTE, Y UNO O MAS EXCIPENTES ADICIONALES COMO LUBRICANTES, AROMATIZANTES, COLORANTES, SABOREANTES Y SUSTANCIAS ACTIVAS SUPERFICIALMENTE. LAS FORMA DE DOSIFICACION ORAL SE SELECCIONA ENTRE TABLETAS, TABLETAS REVESTIDAS, GRANULOS, MICROTABLETAS EN CAPSULAS Y GRANULOS EN CAPSULAS
PE2004000357A 2003-04-11 2004-04-07 Formulacion farmaceutica oral que comprende un antagonista de la bomba de protones y un excipiente basico PE20050414A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10317023A DE10317023A1 (de) 2003-04-11 2003-04-11 Perorale Arzneimittelzubereitung für Protonenpumpenantagonisten
EP03008453 2003-04-11

Publications (1)

Publication Number Publication Date
PE20050414A1 true PE20050414A1 (es) 2005-06-18

Family

ID=33160619

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000357A PE20050414A1 (es) 2003-04-11 2004-04-07 Formulacion farmaceutica oral que comprende un antagonista de la bomba de protones y un excipiente basico

Country Status (19)

Country Link
US (1) US20060204568A1 (es)
EP (1) EP1615624A2 (es)
JP (1) JP2006522776A (es)
KR (1) KR20060002932A (es)
AR (1) AR044004A1 (es)
AU (1) AU2004228961A1 (es)
BR (1) BRPI0409175A (es)
CA (1) CA2526869A1 (es)
CL (1) CL2004000767A1 (es)
EA (1) EA200501565A1 (es)
IS (1) IS8107A (es)
MA (1) MA27772A1 (es)
MX (1) MXPA05010705A (es)
NO (1) NO20055207L (es)
PE (1) PE20050414A1 (es)
RS (1) RS20050756A (es)
TN (1) TNSN05233A1 (es)
TW (1) TW200503783A (es)
WO (1) WO2004089342A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
EP1799211A1 (en) * 2004-10-05 2007-06-27 Altana Pharma AG Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient
US20100047338A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
MY159358A (en) 2007-10-12 2016-12-30 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
CN102743330B (zh) 2008-07-28 2016-03-23 武田药品工业株式会社 药物组合物
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CR20180119A (es) 2015-07-30 2018-03-21 Takeda Pharmaceuticals Co Tableta
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464372A (en) * 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
GB8422461D0 (en) * 1984-09-05 1984-10-10 Wyeth John & Brother Ltd Pyridine derivatives
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4833149A (en) * 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
US5362743A (en) * 1993-03-09 1994-11-08 Pfizer Inc. Aminoquinoline derivatives
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
EA002402B1 (ru) * 1997-03-24 2002-04-25 Бык Гульден Ломберг Хемише Фабрик Гмбх Тетрагидропиридо-соединения
AU7375598A (en) * 1997-05-09 1998-11-27 Sage Pharmaceuticals, Inc. Stable oral pharmaceutical dosage forms
TW580397B (en) * 1997-05-27 2004-03-21 Takeda Chemical Industries Ltd Solid preparation
SK285165B6 (sk) * 1998-09-23 2006-07-07 Altana Pharma Ag Tetrahydropyridoétery, farmaceutický prostriedok s ich obsahom a ich použitie
DE19925710C2 (de) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
UA74339C2 (uk) * 1999-06-07 2005-12-15 Алтана Фарма Аг Форма для введення, що включає інгібітор протонної помпи у вигляді окремих одиниць, та спосіб їх одержання
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
WO2001028559A1 (en) * 1999-10-20 2001-04-26 Eisai Co., Ltd. Method for stabilizing benzimidazole compounds
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same

Also Published As

Publication number Publication date
MA27772A1 (fr) 2006-02-01
CA2526869A1 (en) 2004-10-21
WO2004089342A2 (en) 2004-10-21
JP2006522776A (ja) 2006-10-05
IS8107A (is) 2005-10-31
CL2004000767A1 (es) 2005-05-27
NO20055207L (no) 2005-11-04
TNSN05233A1 (en) 2007-06-11
BRPI0409175A (pt) 2006-04-11
US20060204568A1 (en) 2006-09-14
MXPA05010705A (es) 2005-12-12
TW200503783A (en) 2005-02-01
RS20050756A (sr) 2007-11-15
KR20060002932A (ko) 2006-01-09
WO2004089342A3 (en) 2005-03-10
EP1615624A2 (en) 2006-01-18
AU2004228961A1 (en) 2004-10-21
AR044004A1 (es) 2005-08-24
EA200501565A1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
AR063471A1 (es) Formulaciones para administracion parenteral de compuestos y sus usos
PE20050414A1 (es) Formulacion farmaceutica oral que comprende un antagonista de la bomba de protones y un excipiente basico
JP2023078155A (ja) 剤形およびそれらの使用
JP2013538814A5 (es)
PL1708686T3 (pl) Doustna forma dawkowania fentanylu w postaci musującej o charakterze liniowym oraz sposoby jego podawania
AR063362A1 (es) Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
SV2002000250A (es) Formula de dosis de droga accionada por hidrogel ref. pc10818ajtb/bb
PE20050464A1 (es) Formulacion farmaceutica de la sal sodica del telmisartan
AR058620A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
BR112012023324B8 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
IL179718A0 (en) Pharmaceutical composition containing irbesartan
RU2015127020A (ru) Рецептуры триазина со вторым активным ингредиентом и поверхностно-активным веществом(-и)
Baum et al. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate
UA102885C2 (ru) Таблетка для орального введения, которая содержит тамсулозин и солифенацин
EA037185B1 (ru) Способ лечения психоза, шизофрении или биполярного расстройства
TW200806289A (en) Sustained-release formulation of zonisamide
TW200504014A (en) Indol-5-yl sulfonamide derivatives, their preparation and their use in medicaments
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
MX2024015351A (es) Composicion farmaceutica para tratar y resistir a la coagulacion sanguinea y uso de la misma
SV2003001098A (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
WO2020023898A1 (en) Use of neurokinin-1 antagonists to treat chronic pruritus
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
CN104224702A (zh) 一种含有氟维司群的药物制剂

Legal Events

Date Code Title Description
FX Voluntary withdrawal